XML 51 R40.htm IDEA: XBRL DOCUMENT
v3.25.3

Related Party Transactions, Consulting, Letter Agreements and Strategic Partnership (Details) |  |  |  |  |  |  | 3 Months Ended | 6 Months Ended | 9 Months Ended
--- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Aug. 25, 2025 USD ($) shares | May 27, 2025 USD ($) Intallment | Oct. 22, 2024 shares | May 11, 2024 Intallment | Apr. 11, 2024 shares | Aug. 25, 2022 USD ($) Intallment | Sep. 30, 2025 USD ($) | Sep. 30, 2024 USD ($) | Jun. 30, 2025 USD ($) | Sep. 30, 2025 USD ($) shares | Sep. 30, 2024 USD ($)
Pre-Merger Financing and Waiver Agreements [Abstract] |  |  |  |  |  |  |  |  |  |  |
Granted (in shares) | shares |  |  |  |  |  |  |  |  |  | 22,229,102 |
Proceeds from issuance of common stock |  |  |  |  |  |  |  |  |  | $ 5,626,000 | $ 4,497,000
Dr. Jean Bennett's [Member] |  |  |  |  |  |  |  |  |  |  |
Pre-Merger Financing and Waiver Agreements [Abstract] |  |  |  |  |  |  |  |  |  |  |
Consulting expenses |  |  |  |  |  |  | $ 0 |  |  | $ 0 |
Consultation services receivable period |  |  |  |  |  |  |  |  |  | 1 year |
August 2025 Private Placement [Member] |  |  |  |  |  |  |  |  |  |  |
Pre-Merger Financing and Waiver Agreements [Abstract] |  |  |  |  |  |  |  |  |  |  |
Shares sold (in shares) | shares | 3,138,338 |  |  |  |  |  |  |  |  |  |
Proceeds from issuance of common stock | $ 3,500,000 |  |  |  |  |  |  |  |  |  |
Dr. Pepose [Member] |  |  |  |  |  |  |  |  |  |  |
Pre-Merger Financing and Waiver Agreements [Abstract] |  |  |  |  |  |  |  |  |  |  |
Number of equal installments for vesting | Intallment |  |  |  | 12 |  |  |  |  |  |  |
Consulting expenses |  |  |  |  |  |  | $ 100,000 | $ 100,000 |  | $ 400,000 | $ 300,000
Foundation Fighting Blindness [Member] | 2022 Binding Letter Agreement [Member] |  |  |  |  |  |  |  |  |  |  |
Pre-Merger Financing and Waiver Agreements [Abstract] |  |  |  |  |  |  |  |  |  |  |
Maximum amount of loan |  |  |  |  |  | $ 2,000,000 |  |  |  |  |
Funded amount to support study payable in initial installment |  |  |  |  |  | $ 400,000 |  |  |  |  |
Number of annual installments | Intallment |  |  |  |  |  | 4 |  |  |  |  |
Funded amount to support study payable in annual installment |  |  |  |  |  | $ 400,000 |  |  |  |  |
Payment of final installment amount upon termination of agreement |  | $ 400,000 |  |  |  |  |  |  |  |  |
Payments due related to amount funded to support study |  | 0 |  |  |  |  |  |  |  |  |
Foundation Fighting Blindness [Member] | 2025 Letter Agreement [Member] |  |  |  |  |  |  |  |  |  |  |
Pre-Merger Financing and Waiver Agreements [Abstract] |  |  |  |  |  |  |  |  |  |  |
Funded amount to support study payable in initial installment |  | $ 300,000 |  |  |  |  |  |  |  |  |
Number of annual installments | Intallment |  | 2 |  |  |  |  |  |  |  |  |
Period of agreement termination after study completion |  |  |  |  |  |  |  |  |  | 2 months |
Final installment payable upon receipt of semi-annual reports of study |  | $ 300,000 |  |  |  |  |  |  |  |  |
Payment of initial installment |  |  |  |  |  |  |  |  | $ 300,000 |  |
Potential payment of additional installment |  |  |  |  |  |  |  |  |  | $ 300,000 |
Cam Gallagher [Member] | August 2025 Private Placement [Member] |  |  |  |  |  |  |  |  |  |  |
Pre-Merger Financing and Waiver Agreements [Abstract] |  |  |  |  |  |  |  |  |  |  |
Proceeds from issuance of common stock | 1,000,000 |  |  |  |  |  |  |  |  |  |
Sean Ainsworth [Member] | August 2025 Private Placement [Member] |  |  |  |  |  |  |  |  |  |  |
Pre-Merger Financing and Waiver Agreements [Abstract] |  |  |  |  |  |  |  |  |  |  |
Proceeds from issuance of common stock | $ 100,000 |  |  |  |  |  |  |  |  |  |
Restricted Stock Units [Member] |  |  |  |  |  |  |  |  |  |  |
Pre-Merger Financing and Waiver Agreements [Abstract] |  |  |  |  |  |  |  |  |  |  |
Granted (in shares) | shares |  |  |  |  |  |  |  |  |  | 1,655,361 |
Restricted Stock Units [Member] | Dr. Jean Bennett's [Member] |  |  |  |  |  |  |  |  |  |  |
Pre-Merger Financing and Waiver Agreements [Abstract] |  |  |  |  |  |  |  |  |  |  |
Granted (in shares) | shares |  |  | 100,000 |  |  |  |  |  |  |  |
Restricted Stock Units [Member] | Dr. Pepose [Member] |  |  |  |  |  |  |  |  |  |  |
Pre-Merger Financing and Waiver Agreements [Abstract] |  |  |  |  |  |  |  |  |  |  |
Granted (in shares) | shares |  |  |  |  | 32,000 |  |  |  |  |  |
Stock Options [Member] | Dr. Pepose [Member] |  |  |  |  |  |  |  |  |  |  |
Pre-Merger Financing and Waiver Agreements [Abstract] |  |  |  |  |  |  |  |  |  |  |
Granted (in shares) | shares |  |  |  |  | 48,000 |  |  |  |  |  |

X
- Definition The amount funded to support the study payable in annual installment. + References No definition available. + Details
Name: | ird_AmountFundedToSupportStudyPayableInAnnualInstallment
Namespace Prefix: | ird_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount funded to support the study payable in initial installment at the time of the agreement. + References No definition available. + Details
Name: | ird_AmountFundedToSupportStudyPayableInInitialInstallment
Namespace Prefix: | ird_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Consultation services receivable period from member of the board, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | ird_ConsultationServicesReceivablePeriod
Namespace Prefix: | ird_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate total of expenses of consulting with an entity. + References No definition available. + Details
Name: | ird_ConsultingExpense
Namespace Prefix: | ird_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of installments to paid monthly for the loan repayment. + References No definition available. + Details
Name: | ird_DebtInstrumentNumberOfInstallments
Namespace Prefix: | ird_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The final installment amount funded to support the study payable upon upon receipt of semi-annual reports. + References No definition available. + Details
Name: | ird_FinalInstallmentPayableUponReceiptOfSemiAnnualReportsOfStudy
Namespace Prefix: | ird_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The maximum amount funded to support the study. + References No definition available. + Details
Name: | ird_MaximumAmountFundedToSupportStudy
Namespace Prefix: | ird_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Potential additional installment payment related to the Foundation Fighting Blindness Retinal Degeneration Fund agreement. + References No definition available. + Details
Name: | ird_PaymentOfAdditionalInstallmentToSupportStudyUnderAgreement
Namespace Prefix: | ird_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The aggregate amount paid by the entity related to 2022 Binding Letter Agreement upon its termination. + References No definition available. + Details
Name: | ird_PaymentOfFinalInstallmentUponTerminationOfAgreement
Namespace Prefix: | ird_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payment of initial installment amount related to the Foundation Fighting Blindness agreement. + References No definition available. + Details
Name: | ird_PaymentOfInitialInstallmentToSupportStudyUnderAgreement
Namespace Prefix: | ird_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The payable amount related to funded to support the study due under the 2022 Binding Letter Agreement. + References No definition available. + Details
Name: | ird_PaymentsDueRelatedToAmountFundedToSupportStudy
Namespace Prefix: | ird_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Period of agreement termination after study completion in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | ird_PeriodOfAgreementTerminationAfterStudyCompletion
Namespace Prefix: | ird_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | ird_PreMergerFinancingAndWaiverAgreementsAbstract
Namespace Prefix: | ird_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of equal installments for share-based compensation awards to vest. + References No definition available. + Details
Name: | ird_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEqualInstallmentsForAwardsToVest
Namespace Prefix: | ird_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The cash inflow from the additional capital contribution to the entity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details
Name: | us-gaap_ProceedsFromIssuanceOfCommonStock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of new stock issued during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_TitleOfIndividualAxis=ird_BoardMemberMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ird_FoundationFightingBlindnessMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=ird_BindingLetterAgreement2022Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=ird_LetterAgreement2025Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ird_CamGallagherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ird_SeanAinsworthMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |